OakChart

Bicara Therapeutics Inc

BCAXHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 10:47 AM ET

11.10+0.92 (9.04%)
2026-11-11 16:47 CET
Market cap
673.64 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-220.28 USD m
Free cash flow, TTM
-162.75 USD m
EPS diluted, TTM
-3.46
P/E
-
Compare

Price

BCAX against its 20, 50 and 200-day averages
2050200missearnings
10.0020.0030.007.7M15.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BCAXclose 11.1020-day 12.9850-day 17.38200-day 20.9011.1052w high52w low

64.2% under the 52-week high of 30.99 on 7 Jul 2026. 52-week low 7.87 on 2 Nov 2026. Last 15 sessions, 129.6% high to low

Profile

BCAX
52-week range, 14% of the way up
7.8730.99

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company's bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.

IndexRUT
Employees103
IPOSep 13, 2024
Beta-0.41
ATR, 14d1.32
Rel volume1.34
Short float22.54%
Insider own33.86%
Inst own78.07%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap736.90M
Enterprise Value295.43M
Income-220.28M
Sales0.00M
Book/sh6.17
Cash/sh6.66
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees103
IPOSep 13, 2024

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.80
P/C1.67
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio8.81
Current Ratio8.81
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-3.46
EPS next Y-4.02
EPS next Q-0.99
EPS this Y-47.50%
EPS next Y-8.26%
EPS next 5Y-14.07%
EPS past 3/5Y-53.65% -
Sales past 3/5Y- -
EPS Y/Y TTM-55.27%
Sales Y/Y TTM-
EPS Q/Q-56.50%
Sales Q/Q-
EarningsNov 09 BMO
EPS/Sales Surpr.-26.83% -

Ownership

Insider Own33.86%
Insider Trans-0.72%
Inst Own78.07%
Inst Trans-4.10%
ROA-49.76%
ROE-54.24%
ROIC-53.80%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-14.51%
SMA50-36.15%
SMA200-46.90%
Trades-

Technical

Shs Outstand66.35M
Shs Float43.76M
Short Float22.54%
Short Ratio8.74
Short Interest9.86M
52W High30.99 -64.18%
52W Low7.87 41.04%
Volatility10.50% 12.74%
ATR (14)1.32
RSI (14)39.05
Beta-0.41
Rel Volume1.34
Avg Volume1.13M
Volume359,794

Performance

Perf Week24.86%
Perf Month-35.99%
Perf Quarter-53.03%
Perf Half Y-47.12%
Perf YTD-34.05%
Perf Year-24.64%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.29
Target Price32.17
Prev Close10.18
Price11.10
Change %9.04%

Analyst ratings

latest 10 of 17
DateActionAnalystRating changeTargetImplied
Oct 30, 2026DowngradeGGoldmanNeutral → Sell$8-27.9%
Aug 19, 2026InitiatedBBMO Capital MarketsOutperform$35+215.3%
May 11, 2026InitiatedGGuggenheimBuy$42+278.4%
Mar 25, 2026InitiatedBBofA SecuritiesBuy$35+215.3%
Jan 29, 2026InitiatedCCitizens JMPMkt Perform$31+179.3%
Jan 08, 2026InitiatedBBTIG ResearchBuy$28+152.3%
Dec 18, 2025InitiatedMMizuhoNeutral$18+62.2%
Aug 19, 2025InitiatedPPiper SandlerOverweight$36+224.3%
May 23, 2025UpgradeWWells FargoUnderweight → Equal Weight$8-27.9%
Apr 17, 2025InitiatedWWells FargoUnderweight$8-27.9%

Peers

Mkt cap
TickerCompanyMkt cap
GMABGenmab ADR32.38B
KURAKura Oncology Inc704.10M
CBIOCrescent Biopharma Inc530.04M
SMMTSummit Therapeutics Inc13.23B
XNCRXencor Inc2.98B
JANXJanux Therapeutics Inc744.93M
EXELExelixis Inc17.13B
IDYAIdeaya Biosciences Inc3.11B
CHRSCoherus Oncology Inc95.39M
MRKMerck & Co Inc358.82B

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
DAVID RABENOfficerOct 21 '26Proposed Sale18.1224,777449,026Oct 21 04:55 PM
Cohlhepp RyanPresident, COO & Interim CEOSep 08 '26Option Exercise3.7917,50066,322199,141Sep 10 04:23 PM
Cohlhepp RyanPresident, COO & Interim CEOSep 08 '26Sale22.9017,500400,716181,641Sep 10 04:23 PM
Hyep IvanOfficerSep 08 '26Proposed Sale22.6412,500283,000Sep 08 04:05 PM
Cohlhepp RyanOfficerSep 08 '26Proposed Sale22.6417,500396,200Sep 08 04:04 PM
Hyep IvanChief Financial OfficerAug 10 '26Option Exercise3.7912,50047,372142,355Aug 12 04:19 PM
Hyep IvanChief Financial OfficerAug 10 '26Sale27.9712,500349,591129,855Aug 12 04:19 PM
Mazumdar ClaireChief Executive OfficerAug 10 '26Option Exercise3.7910,00037,898372,152Aug 12 04:19 PM
Mazumdar ClaireChief Executive OfficerAug 10 '26Sale27.9810,000279,750362,152Aug 12 04:19 PM
Cohlhepp RyanPresident and COOAug 10 '26Option Exercise3.7918,75071,059200,391Aug 12 04:19 PM
Cohlhepp RyanPresident and COOAug 10 '26Sale27.9818,750524,533181,641Aug 12 04:19 PM
Hyep IvanOfficerAug 10 '26Proposed Sale27.8312,500347,875Aug 10 04:18 PM
Cohlhepp RyanOfficerAug 10 '26Proposed Sale27.8318,750521,812Aug 10 04:16 PM
Mazumdar ClaireOfficerAug 10 '26Proposed Sale27.8310,000278,300Aug 10 04:09 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 156
  • Bicara Therapeutics Misses As Losses Widen; Enrollment Milestone Overshadowed By A Competitive Reset In Head And Neck Cancer (Earnings Whispers) +15.38%
  • Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire)
  • Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Bicara Heads Into Third-Quarter Report After 60% Slide With Leadership And Cash Under Scrutiny (Earnings Whispers) -13.14%
  • Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET (GlobeNewswire)
  • Loading…
  • Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Bicara Therapeutics stock gains 3% as pivotal trial enrollment advances (InvestorsHub) -14.32%
  • Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth (GlobeNewswire)
  • Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET (GlobeNewswire)
  • Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors (GlobeNewswire)
  • Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-1.040-0.820-1.0400.000.0012
2026Q22026-08-11-0.820-0.820-0.8160.000.0014
2026Q12026-05-11-0.930-0.649-0.9260.000.0014
2025Q42026-03-30-0.680-0.672-0.6780.000.0012
2025Q32025-11-10-0.670-0.541-0.6660.000.009
2025Q22025-08-12-0.500-0.554-0.5020.000.007
2025Q12025-05-13-0.680-0.415-0.6770.000.008
2024Q42025-03-27-0.390-0.329-0.3850.000.008
2024Q32024-11-12-1.600-0.410-0.3210.000.005
2024Q22024-08-28-0.440--0.3130.00--
2026Q4---0.985--0.0012
2027Q1---0.982--0.006
2027Q2---1.005--0.006
2027Q3---1.012--0.006
2027Q4---1.055--0.006

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2024FY-4.050-2.420-1.2490.000.00
2025FY-2.520-2.516-2.5200.000.00
2026FY--3.705--0.00
2027FY--3.973--0.00
2028FY--3.740--39.97
2029FY--2.505--209.1
2030FY-0.726--540.37

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0911000.000.000.00
2026Q4S2026-08-1910000.000.000.00
2026Q4S2026-08-1111000.000.000.00
2026Q4S2026-07-0811000.000.000.00
2026Q4S2026-05-1112000.000.000.00
2026Q4S2026-05-0811000.000.000.00
2026Q4S2026-03-3010000.000.000.00
2026Q4S2026-01-285000.000.000.00
2026Q4S2025-11-114000.000.000.00
2026Q4S2025-11-104000.000.000.00
2026Q4S2025-11-092000.000.000.00
2026Q4R2026-11-101208-0.99-1.17-0.47
2026Q4R2026-11-091206-0.95-1.17-0.47
2026Q4R2026-11-031200-0.86-0.97-0.47

Estimate history

EPS, annual-0.696-0.955-1.249-2.523-3.4619
Period2022202320242025TTM
EPS, quarterly-0.321-0.385-0.677-0.502-0.666-0.678-0.926-0.816-1.042
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000
Period2022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual54.4154.4154.4456.60166.353
Period2022202320242025MRQ
Shares, quarterly54.4154.4454.52954.55654.61256.60165.54765.93166.353
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Total Revenue0.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.190.100.060.020.01
Gross Profit-0.19-0.10-0.06-0.02-0.01
Selling, General and Administrative Excl. Other236.84155.5082.3339.8737.65
Research and Development182.74125.1063.6230.6231.31
Other Operating Expense0.000.000.000.000.00
Operating Income-237.03-155.60-82.39-39.89-37.66
Interest Expense0.000.000.000.000.11
Unusual Expense0.000.000.0013.400.00
Net Income Before Taxes-220.06-137.73-67.81-51.98-37.84
Income Taxes0.220.220.190.010.00
Consolidated Net Income-220.28-137.95-68.00-51.98-37.84
Net Income From Continuing Operations-220.28-137.95-68.00-51.98-37.84
Net Income-220.28-137.95-68.00-51.98-37.84
EPS (Recurring)-3.22-2.52-1.25-0.78-0.70
EPS (Basic, Before Extraordinaries)-3.46-2.52-1.25-0.96-0.70
EPS (Diluted)-3.46-2.52-1.25-0.96-0.70
EBITDA-236.84-155.50-82.33-39.87-37.65
Non-Operating Income (Expense)16.9617.8714.581.31-0.08
Other After Tax Adjustments0.000.000.000.000.00
Stock Option Compensation Expense22.5311.855.841.500.64
Shares Outstanding66.3556.6054.4454.4154.41
Market Capitalization673.64673.64947.92925.07-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.060.040.040.040.020.020.020.01
Gross Profit-0.06-0.04-0.04-0.04-0.02-0.02-0.02-0.01
Selling, General and Administrative Excl. Other75.6559.9160.2041.0840.6532.0041.7726.62
Research and Development56.4845.7747.5032.9932.9824.8034.3319.88
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-75.71-59.95-60.24-41.12-40.68-32.02-41.79-26.64
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-71.19-55.38-56.16-37.33-36.29-27.34-36.77-20.77
Income Taxes0.050.060.050.050.040.050.070.19
Consolidated Net Income-71.25-55.44-56.21-37.39-36.33-27.39-36.85-20.96
Net Income From Continuing Operations-71.25-55.44-56.21-37.39-36.33-27.39-36.85-20.96
Net Income-71.25-55.44-56.21-37.39-36.33-27.39-36.85-20.96
EPS (Recurring)-1.04-0.82-0.93-0.68-0.67-0.50-0.68-0.38
EPS (Basic, Before Extraordinaries)-1.04-0.82-0.93-0.68-0.67-0.50-0.68-0.39
EPS (Diluted)-1.04-0.82-0.93-0.68-0.67-0.50-0.68-0.39
EBITDA-75.65-59.91-60.20-41.08-40.65-32.00-41.77-26.62
Non-Operating Income (Expense)4.524.584.083.794.394.685.015.87
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.886.514.633.512.862.762.732.51
Shares Outstanding66.3565.9365.5556.6054.6154.5654.5354.44
Market Capitalization673.641,950.751,260.29921.98861.55506.64709.04947.92

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY
Cash & Short Term Investments414.80489.71230.444.16
Short Term Receivables0.000.000.000.00
Inventories0.000.000.000.00
Other Current Assets7.2512.820.630.83
Total Current Assets422.05502.53231.074.98
Net Property, Plant & Equipment2.030.840.810.64
Total Investments and Advances0.000.000.000.00
Deferred Tax Assets98.3059.20--
Other Assets6.916.622.091.08
Total Assets529.30569.20233.986.70
Short Term Debt Incl. Current Port. of LT Debt1.120.610.280.00
Accounts Payable7.794.513.195.14
Other Current Liabilities20.0412.8811.6118.76
Total Current Liabilities28.9517.9915.0923.90
Long Term Debt0.590.130.370.00
Provision for Risks Charges0.000.000.000.00
Deferred Tax Liabilities98.3059.20--
Other Liabilities0.000.000.020.09
Total Liabilities127.8477.3215.4723.98
Non-Equity Reserves0.000.000.000.00
Preferred Stock - Carrying Value0.000.00367.2881.53
Common Equity401.45491.88-148.77-98.80
Total Shareholders Equity401.45491.88218.51-17.28
Accumulated Minority Interest0.000.000.000.00
Total Equity401.45491.88218.51-17.28
Total Liabilities & Stockholders Equity529.30569.20233.986.70
Book Value Per Share7.099.04-2.73-1.82
Tangible Book Value Per Share7.099.04-2.73-1.82
Full-Time Employees10355--
Price to Book Ratio1.651.861.82-
Return on Assets-25.12-16.93-43.20-
Return on Equity-30.88-19.14-51.67-
Return on Invested Capital-34.31-13.82-23.75-
Quick Ratio14.5827.9315.320.21
Current Ratio14.5827.9315.320.21

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY
Net Income-220.28-137.95-68.00-51.98-37.84
Depreciation0.190.100.060.020.01
Other Funds (Non Cash)30.6816.207.3215.960.81
Funds from Operations-189.41-121.64-60.62-36.00-37.02
Extraordinary Item0.000.000.000.000.00
Changes in Working Capital27.6814.81-14.13-9.624.95
Cash from Operating Activities-161.73-106.83-74.75-45.63-32.08
Capital Expenditures-1.02-0.28-0.07-0.59-0.19
Net Assets From Acquisitions0.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.060.000.00
Purchase or Sale of Investments-127.02-318.170.000.000.00
Purchase of Investments-327.02-318.170.000.000.00
Sale Or Maturity of Investments200.000.000.000.000.00
Other Uses0.000.000.000.000.00
Other Sources0.000.000.000.000.00
Cash from Investing Activities-128.04-318.45-0.01-0.59-0.19
Cash Dividends Paid0.000.000.000.000.00
Change in Capital Stock200.1232.26334.03272.5031.70
Repurchase of Common Pref Stock0.000.000.000.000.00
Sale of Common Pref Stock200.1232.26334.03272.5031.70
Proceedsfrom Stock Options191.2629.50332.43272.3531.54
Issuance or Reduction of Debt, Net0.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.00
Cash from Financing Activities200.1232.26334.03272.5031.70
Net Change in Cash-89.65-393.03259.27226.28-0.57
Free Cash Flow-162.75-107.11-74.82-46.21-32.27
Preferred Dividends (Cash Flow)-0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments442.35497.26539.75414.80290.17436.61
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets9.066.565.167.257.217.79
Total Current Assets451.41503.82544.91422.05297.37444.39
Net Property, Plant & Equipment1.691.511.772.032.102.35
Total Investments and Advances0.000.000.000.00117.420.00
Deferred Tax Assets---98.30--
Other Assets7.546.916.916.917.796.84
Total Assets460.64512.24553.60529.30424.69453.59
Short Term Debt Incl. Current Port. of LT Debt0.881.161.141.121.091.07
Accounts Payable3.648.467.447.793.662.91
Other Current Liabilities46.7133.8530.7620.0416.2713.24
Total Current Liabilities51.2343.4839.3428.9521.0317.23
Long Term Debt0.000.000.300.590.881.16
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---98.30--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities51.2343.4839.64127.8421.9118.39
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity409.41468.77513.96401.45402.78435.20
Total Shareholders Equity409.41468.77513.96401.45402.78435.20
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity409.41468.77513.96401.45402.78435.20
Total Liabilities & Stockholders Equity460.64512.24553.60529.30424.69453.59
Book Value Per Share6.177.117.847.097.387.98
Tangible Book Value Per Share6.177.117.847.097.387.98
Full-Time Employees---103--
Price to Book Ratio1.653.792.802.281.981.10
Return on Assets-49.76-38.38-30.50-25.12-25.61-31.00
Return on Equity-54.24-41.01-32.34-30.88-26.64-32.71
Return on Invested Capital-17.40-11.83-10.93-9.30-9.00-6.28
Quick Ratio8.8111.5913.8514.5814.1425.80
Current Ratio8.8111.5913.8514.5814.1425.80

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-71.25-55.44-56.21-37.39-36.33-27.39
Depreciation0.060.040.040.040.020.02
Other Funds (Non Cash)10.448.756.475.013.903.70
Funds from Operations-60.75-46.64-49.70-32.33-32.41-23.67
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital4.622.4312.198.443.16-1.93
Cash from Operating Activities-56.13-44.21-37.51-23.89-29.25-25.59
Capital Expenditures-0.66-0.06-0.06-0.24-0.040.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments39.00-184.93101.00-82.09-236.080.00
Purchase of Investments0.00-244.930.00-82.09-236.080.00
Sale Or Maturity of Investments39.0060.00101.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities38.34-184.99100.94-82.33-236.120.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.212.33163.3431.230.440.14
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.212.33163.3431.230.440.14
Proceedsfrom Stock Options0.000.00161.7629.500.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities3.212.33163.3431.230.440.14
Net Change in Cash-14.58-226.86226.78-74.99-264.93-25.46
Free Cash Flow-56.79-44.27-37.57-24.12-29.29-25.59

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3022.54%9.9M43.8M1.02M
2026-10-1523.53%10.3M43.8M656.13K
2026-09-3024.57%10.7M43.5M626.72K
2026-09-1525.72%11.2M43.5M724.06K
2026-08-3124.92%10.8M43.5M724.07K
2026-08-1424.13%10.5M43.4M722.26K
2026-07-3124.49%9.6M39.2M687.19K
2026-07-1523.77%9.3M39.2M680.55K
2026-06-3026.95%10.1M37.6M669.35K
2026-06-1527.05%10.2M37.6M537.09K
2026-05-2926.85%10.1M37.6M554.33K
2026-05-1522.53%9.8M43.7M588.92K
2026-04-3021.56%8.9M41.3M549.34K
2026-04-1522.59%9.3M41.3M550.73K
2026-03-3125.39%9.6M38.0M524.02K
2026-03-1325.47%9.4M36.8M533.27K
2026-02-2729.17%9.3M31.8M529.57K
2026-02-1327.74%8.8M31.8M542.25K
2026-01-3027.81%8.9M32.0M600.43K
2026-01-1527.85%8.9M32.0M672.49K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.506.0010.500.000.0000.000.000.988-0.0160.001
call5.003.507.500.008.4390.000.000.977-0.0150.001
call7.501.005.400.005.7620.000.000.959-0.0140.002
call10.000.004.900.306.7411,0520.000.783-0.2550.005
call12.500.000.900.202.1131,3690.000.435-0.0810.007
call15.000.004.200.008.0510.000.000.647-0.2800.006
call17.500.004.901.508.6351400.000.630-0.3070.006
call20.000.004.901.009.16480.000.000.619-0.3290.007
call22.500.004.900.009.6080.000.000.610-0.3480.007
call25.000.004.901.309.9891.000.000.603-0.3630.007
call30.000.004.900.0310.6171.000.000.592-0.3890.007
put2.500.004.000.000.0000.000.000.0000.0000.000
put5.000.000.050.0531.48024.000.00-0.004-0.0360.000
put7.500.000.050.1313.4065310.00-0.109-0.2350.003
put10.000.004.900.008.1420.000.00-0.252-0.2160.005
put12.500.004.903.705.8324.000.00-0.287-0.2700.006
put15.002.506.500.705.4470.000.00-0.664-0.1010.006
put17.504.609.001.356.16828.000.00-0.685-0.1250.006
put20.007.4011.500.006.5890.000.00-0.708-0.1390.006
put22.509.6014.000.007.0470.000.00-0.723-0.1490.006
put25.0012.5016.500.007.5810.000.00-0.735-0.1560.006
put30.0017.5021.500.008.0830.000.00-0.750-0.1690.006

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-10-21144Filing for proposed sale of securities under Rule 144.SEC
2026-10-07SCHEDULE 13G/ASEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-08-258-KCurrent report2026-08-21SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-143Initial statement of beneficial ownership of securities2026-08-12SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-11S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-10144Filing for proposed sale of securities under Rule 144.SEC
2026-08-10144Filing for proposed sale of securities under Rule 144.SEC
2026-08-10144Filing for proposed sale of securities under Rule 144.SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-28SEC
2026-07-293Initial statement of beneficial ownership of securities2026-07-28SEC
2026-07-293Initial statement of beneficial ownership of securities2026-07-28SEC
2026-07-288-KCurrent report2026-07-23SEC
2026-07-27SCHEDULE 13GSEC
2026-07-144Statement of changes in beneficial ownership of securities2026-07-10SEC
2026-07-10144Filing for proposed sale of securities under Rule 144.SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0900400.72K1
2026-08001.15M3
2026-07001.92M4
2026-060000
2026-0500742.11K3
2026-0400979.18K4
2026-03002.58M15
2026-024.80M165.50K1
2026-0100106.14K3
2025-1200402.04K2
2025-11001.55M6

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.11.04%
T. Rowe Price Investment Management, Inc.9.65%
Siren, L.L.C.8.53%
Vestal Point Capital, LP7.99%
Deep Track Capital, LP6.24%
BlackRock, Inc.5.86%
Jupiter Topco LLC4.83%
TPG GP A, LLC4.58%
Red Tree Management, LLC4.41%
VANGUARD CAPITAL MANAGEMENT LLC3.37%

Funds

Fund% owned
T. Rowe Price Small-Cap Stock Fund, Inc.3.32%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.55%
T. Rowe Price Institutional Small-Cap Stock Fund1.78%
iShares Russell 2000 ETF1.75%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.67%
Select Biotechnology Portfolio1.36%
Franklin Small Cap Growth Fund0.95%
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund0.93%
T. Rowe Price Small-Cap Value Fund, Inc.0.92%
T. Rowe Price Health Sciences Fund, Inc.0.90%

OakChart. BCAX. Cached 15 minutes.